2-(溴甲基)-1-氯-3-氟-4-甲基苯 | 261762-88-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(溴甲基)-1-氯-3-氟-4-甲基苯
• 中文别名: 6-氯-2-氟-3-甲基溴苄
• 英文名称: 2-(bromomethyl)-1-chloro-3-fluoro-4-methylbenzene
• 英文别名: 6-Chloro-2-fluoro-3-methylbenzyl bromide
• CAS: 261762-88-3
• 化学式: C₈H₇BrClF
• 分子量: 237.499
• InChiKey: QWQVTYYKMSFGGP-UHFFFAOYSA-N

物化性质

• 熔点：
  52-56℃
• 沸点：
  103°C/3mm
• 密度：
  1.569±0.06 g/cm3(Predicted)
• 闪点：
  103°C/3mm

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  8
• 海关编码：
  2903999090

反应信息

• 作为反应物：
  描述：

  2-(溴甲基)-1-氯-3-氟-4-甲基苯 在 lithium hydroxide monohydrate 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  The discovery of potent small molecule cyclic urea activators of STING

  摘要：

  DOI：

  10.1016/j.ejmech.2021.114087

文献信息

• INHIBITORS OF STEAROYL-COA DESATURASE
  申请人：Gillespie Paul

  公开号：US20090149466A1

  公开（公告）日：2009-06-11

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

  提供以下式(I)化合物： 以及药用可接受的盐，其中取代基如说明书中所披露。这些化合物以及包含它们的药物组合物可用于治疗诸如肥胖等疾病。
• (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS
  申请人：Ballell Pages Lluis

  公开号：US20120095064A1

  公开（公告）日：2012-04-19

  A compound of Formula (I) wherein: either X is N and Y is CR 5 or X is C and Y is S; Z is selected from N and CH; R 1 is selected from H and Me; R 2 is selected from H, OH, OMe and Me; each R 3 is independently selected from C 1-3 alkyl, F, Cl, Br, CF 3 and NH 2 ; R 4 is selected from Me, CF 3 , NO 2 and CHF 2 ; R 5 is selected from H, Me and CHF 2 ; R 6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  一个由Formula (I)组成的化合物 其中：X为N且Y为CR5，或者X为C且Y为S；Z从N和CH中选择；R1从H和Me中选择；R2从H、OH、OMe和Me中选择；每个R3独立地从C1-3烷基、F、Cl、Br、CF3和NH2中选择；R4从Me、CF3、NO2和CHF2中选择；R5从H、Me和CHF2中选择；R6从H和Me中选择；p为0-3，提供了含有它们的组合物，它们在治疗中的使用，例如在结核病治疗中的使用，以及制备这类化合物的方法。
• Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives
  申请人：Galley Guido

  公开号：US20070197621A1

  公开（公告）日：2007-08-23

  The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R 1 , R 2 , A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

  本发明涉及一种治疗抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神分裂症等精神障碍、帕金森病等神经系统疾病、阿尔茨海默病等神经退行性疾病、癫痫、偏头痛、高血压、物质滥用、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍以及心血管疾病的方法，包括向个体施用化合物I的治疗有效量，其中R、R1、R2、A和n如规范中所定义，以及其药用活性盐。该发明还涉及化合物I的新颖化合物、含有它们的药物组合物以及它们的制备方法。
• [EN] SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY<br/>[FR] ACIDES 2-NAPHTOÏQUE SUBSTITUÉS EN TANT QU'ANTAGONISTES DE L'ACTIVITÉ DE GPR105
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2009070873A1

  公开（公告）日：2009-06-11

  Substituted 2-naphthoic acids of structural formula I are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome.

  结构式I中的2-萘甲酸替代物对GPR105蛋白的生物活性具有拮抗作用。它们可用于治疗、控制或预防对该受体拮抗有响应的疾病，如糖尿病，特别是2型糖尿病，胰岛素抵抗，高血糖，脂质紊乱，肥胖，动脉粥样硬化以及与代谢综合征相关的疾病。
• [EN] SUBSTITUTED BENZYLINDAZOLES FOR USE AS BUB1 KINASE INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES.<br/>[FR] BENZYLINDAZOLES SUBSTITUÉS POUR L'UTILISATION EN TANT QU'INHIBITEURS DE BUB1 KINASE DANS LE TRAITEMENT DE MALADIES D'HYPERPROLIFÉRATION
  申请人：BAYER PHARMA AG

  公开号：WO2013050438A1

  公开（公告）日：2013-04-11

  Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.

  式(I)的化合物是Bub1激酶的抑制剂，其生产过程以及它们作为药物的用途。